Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.17 and traded as low as $7.01. Titan Pharmaceuticals shares last traded at $7.01, with a volume of 602 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of Titan Pharmaceuticals in a research note on Tuesday. They issued a “sell” rating for the company.
Read Our Latest Stock Analysis on TTNP
Titan Pharmaceuticals Stock Performance
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- 3 Tickers Leading a Meme Stock Revival
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How to invest in blue chip stocks
- Merger or Not, Albertson’s Companies is a Good Buy
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.